<DOC>
	<DOC>NCT00376584</DOC>
	<brief_summary>This is a 12-week clinical trial in lipid clinic patients for whom niacin therapy is appropriate to evaluate the efficacy of MK0524 to improve the tolerability of extended-release niacin. There will be 6 scheduled clinic visits and 3 treatment arms.</brief_summary>
	<brief_title>Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Patient is appropriate candidate for niacin therapy Patients with evidence of ischemic cardiovascular disease must be on a statin and have LDLC &lt;130 mg/dL at V1 Patients with diabetes mellitus and no evidence of ischemic cardiovascular disease must have LDLC &lt;130 mg/dL at V1 Nondiabetic patients with 2 or more risk factors for coronary heart disease and no ischemic cardiovascular disease must have LDLC &lt;160 mg/dL at V1 Patient has TG &lt;500 mg/dL (5.65 mmol/L) at V1 A patients historic serum or plasma lipid values measured within 6 months from Visit 1 may be used to meet lipid inclusion criteria ALL OTHER PATIENTS DO NOT REQUIRE SPECIFIC LIPID ENTRY CRITERIA Patients with unstable doses of medications Pregnant or lactating women, or women intending to become pregnant are excluded Patients with diabetes mellitus that is poorly controlled, unstable or newly diagnosed Patients with: chronic heart failure, uncontrolled/unstable cardiac arrhythmias, unstable hypertension, active or chronic hepatobiliary disorder or hepatic disease, HIV positive, gout (within 1 year)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Primary Hypercholesteremia</keyword>
	<keyword>Mixed Hyperlipidemia</keyword>
</DOC>